Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Adaptimmune Therapeutics PLC - - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ADAP
Nasdaq
8731
https://www.adaptimmune.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Adaptimmune Therapeutics PLC -
Publication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial Sarcoma
- Jan 9th, 2023 1:00 pm
Even after rising 48% this past week, Adaptimmune Therapeutics (NASDAQ:ADAP) shareholders are still down 72% over the past five years
- Jan 8th, 2023 12:06 pm
Mesa Labs and Eldorado Gold have been highlighted as Zacks Bull and Bear of the Day
- Dec 28th, 2022 11:51 am
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
- Dec 27th, 2022 2:05 pm
Adaptimmune Announces Initiation of Biologics License Application (BLA) Submission for Afami-cel, Its First-Gen Engineered TCR T-cell Therapy targeting MAGE-A4, For the Treatment of Synovial Sarcoma
- Dec 23rd, 2022 6:20 pm
Hedge funds investors may adopt severe steps after Adaptimmune Therapeutics plc's (NASDAQ:ADAP) latest 20% drop adds to a year losses
- Dec 10th, 2022 2:02 pm
Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain Consistent
- Nov 18th, 2022 1:00 pm
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
- Nov 13th, 2022 12:28 pm
Lab notes: Adaptimmune to reduce workforce; NRx completes $11M debt financing
- Nov 11th, 2022 3:52 pm
Adaptimmune Therapeutics Third Quarter 2022 Earnings: Beats Expectations
- Nov 10th, 2022 11:03 am
Why Adaptimmune Therapeutics Stock Is Glowing Green Today
- Nov 8th, 2022 8:11 pm
Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Strong Position To Grow Its Business
- Nov 8th, 2022 2:41 pm
Adaptimmune Reports Third-Quarter Financial Results and Business Update
- Nov 8th, 2022 12:30 pm
Adaptimmune Reports Increased Response Rate and Durability of Response in Its Phase 1 SURPASS trial; ORR Now 52% Across Ovarian, Urothelial, and Head & Neck Cancers
- Nov 8th, 2022 12:00 pm
Adaptimmune to Report Q3 2022 Financial and Business Updates on Tuesday, November 8, 2022
- Oct 27th, 2022 4:27 pm
GSK Transfers Cell Therapy Program Rights To Adaptimmune, Terminates Second Cell Therapy Pact In A Day
- Oct 25th, 2022 3:12 pm
Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK
- Oct 25th, 2022 12:00 pm
Adaptimmune's Cancer Candidate Shows 44% Response Rate In Pretreated Ovarian, Urothelial, Head & Neck Cancers
- Sep 9th, 2022 2:23 pm
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
- Sep 9th, 2022 11:00 am
Adaptimmune to Host Live, Virtual Event to Review Phase 1 SURPASS Trial Data and Outline Plans for Further Development in SURPASS Family of Trials
- Aug 25th, 2022 12:00 pm
Scroll